FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

• P. Jimenez-Fonseca ^[1] ; A. Carmona-Bayonas ^[9] ; C. Calderon ^[2] ; J. Fontcuberta Boj ^[10] ; C. Font ^[11] ; R. Lecumberri ^[3] ; M. Monreal ^[4] ; A. J. Muñoz Martín ^[5] ; R. Otero ^[6] ; A. Rubio ^[7] ; P. Ruiz-Artacho ^[8] ; C. Suarez Fernández ^[12] ; E. Colome ^[13] ; P. Pérez Segura ^[8]
  1. [1] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  2. [2] Universitat de Barcelona

     Universitat de Barcelona

     Barcelona, España

     
  3. [3] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  4. [4] Hospital Universitari Germans Trias i Pujol

     Hospital Universitari Germans Trias i Pujol

     Barcelona, España

     
  5. [5] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  6. [6] Instituto de Biomedicina de Sevilla

     Instituto de Biomedicina de Sevilla

     Sevilla, España

     
  7. [7] Hospital Virgen de la Salud

     Hospital Virgen de la Salud

     Toledo, España

     
  8. [8] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  9. [9] Hospital Universitario Morales Meseguer, España
  10. [10] Hospital Universitari de la Santa Creu i Sant Pau, España
  11. [11] Hospital Universitari Clínic Barcelona, España
  12. [12] Hospital Universitario La Princesa, España
  13. [13] LEO Pharma Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 8 (August 21017), 2017, págs. 997-1009
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction Decision-making in cancer-related venous thromboembolism (VTE) is often founded on scant lines of evidence and weak recommendations. The aim of this work is to evaluate the percentage of agreement surrounding a series of statements about complex, clinically relevant, and highly uncertain aspects to formulate explicit action guidelines.

    Materials and methods Opinions were based on a structured questionnaire with appropriate scores and were agreed upon using a Delphi method. Questions were selected based on a list of recommendations with low evidence from the Spanish Society of Oncology Clinical Guideline for Thrombosis. The questionnaire was completed in two iterations by a multidisciplinary panel of experts in thrombosis.

    Results Of the 123 statements analyzed, the panel concurred on 22 (17%) and another 81 (65%) were agreed on by qualified majority, including important aspects of long-term and prolonged anticoagulation, major bleeding and rethrombosis management, treatment in special situations, catheter-related thrombosis and thromboprophylaxis. Among them, the panelists agreed the incidental events should be equated to symptomatic ones, long-term and extended use of full-dose low-molecular weight heparin, and concluded that the Khorana score is not sensitive enough to uphold an effective thromboprophylaxis strategy.

    Conclusion Though the level of consensus varied depending on the scenario presented, overall, the iterative process achieved broad agreement as to the general treatment principles of cancer-associated VTE. Clinical validation of these statements in genuine practice conditions would be useful.